Axovant Sciences (AXON): Key Differences From Lundbeck - Piper Jaffray
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Axovant Sciences (NYSE: AXON) after shares traded off when competitor, Lundbeck, announced that its first Phase III data with idalopirdine in Alzheimer’s missed the primary endpoint.
Idalopirdine shares the putative 5-HT6 antagonist MOA with Axovant’s RVT-101 but the analyst doesn't believe this result has predictive value for the ongoing '101 Phase III. Therefore he continues to see potential for this target in AD.
Key differences between the two candidates and Phase III programs:
-idalopirdine faced challenges on liver toxicity and potency
-this drug profile and protocol prioritized speed over thoroughness
In contrast, the analyst sees RVT-101 as the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. In addition, Axovant has already made significant progress on enrollment and in advance of 2017 results.
No change to the price target of $32.
Shares of Axovant Sciences closed at $15.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Starts Tabula Rasa Healthcare (TRHC) at Buy
- H.C. Wainwright Downgrades Vertex (VRTX) to Neutral
- Jefferies Raises Price Target on FMC Technologies (FTI) After Adjusting Estimates
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesPiper Jaffray, Charles Duncan
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!